Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News Ateganosine Phase 3 marks inflection point for MAIA Biotechnology with 2026 milestones in focus Find out how MAIA Biotechnology’s Phase 3 ateganosine trial and 2026 milestones could reshape its regulatory path and investor narrative. bySoujanya RaviJanuary 23, 2026